ArticleScientific reports2025
MultiFG: integrating molecular fingerprints and graph embeddings via attention mechanisms for robust drug side effect prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A unified multi-scale deep learning framework for molecular property prediction that bridges molecular structures and fingerprinting.Communications chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Accurate prediction of drug side effect frequencies is critical for drug safety assessment but remains challenging due to the high cost of clinical trials and the limited generalizability of existing models. We propose Multi Fingerprint and Graph Embedding model (MultiFG), a novel deep learning framework that integrates diverse molecular fingerprint types, graph-based embeddings, and similarity features of drug-side effect pairs. MultiFG incorporates attention-enhanced convolutional networks and utilizes the recently developed Kolmogorov-Arnold Networks (KAN) as the prediction layer to effectively capture complex relationships. In the task of predicting side effect associations for approved drugs, MultiFG achieved an AUC of 0.929, precision@15 of 0.206, and recall@15 of 0.642, outperforming the previous state-of-the-art by 0.7% points, 7.8%, and 30.2%, respectively. For side effect frequency prediction, MultiFG attained an RMSE of 0.631 and an MAE of 0.471, representing improvements of 0.413 and 0.293 over the best existing model. Moreover, MultiFG demonstrated strong generalization performance when predicting side effects for novel drugs. Overall, MultiFG offers a significant advancement in both side effect association and frequency prediction tasks, providing a practical and powerful tool for risk assessment across both marketed and investigational drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.